poisar

Stocks · News reference

Barclays Initiates Coverage On Cooper Companies with Equal-Weight Rating, Announces Price Target of $60

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

COO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Brendan Coffey

    Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?

    Cooper Companies director Paul Keel purchased 4,701 shares worth $250,000 at $53.18 per share on September 11, 2026, following a 21% year-long stock decline. The insider buy is viewed as a bullish signal, suggesting confidence in the company's long-term growth prospects. Keel, who recently joined Cooper's board in May, brings extensive experience from his CEO role at Envista Holdings and prior positions at 3M.

    COONVSTMMM
  2. Glancy Prongay Wolke & Rotter Llp

    Securities Fraud Investigation Into The Cooper Companies, Inc. (COO) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

    The Cooper Companies faces a securities fraud investigation following disappointing Q3 2026 results. The company reported flat year-over-year revenue of $717 million, attributed to U.S. channel inventory reductions. Cooper lowered full-year guidance by approximately 1.4% in revenue and 1.8% in EPS, causing shares to decline 14.67% on September 10, 2026.

    COO
  3. Brendan Coffey

    Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?

    Lawrence Erik Kurzius, a Director at Cooper Companies, purchased 10,000 shares worth $549,300 at $54.93 per share on September 16, 2026, increasing his total holdings to 31,099 shares. The insider buy signals confidence in the company's recovery prospects following a 16% stock decline over the past year. The article notes that insider purchases typically predict higher share prices within 30 days and suggest management believes in the company's long-term growth, particularly after deciding to retain its surgical unit rather than divest it.

    COOMKCMKC.V